On the other hand, a significant antiproliferative effect of TZDs on several types of cancer has been reported (Tseng, 2017; Bolden et al., 2012), together with the observation that some PPARγ agonists seem to contribute to improve the chemical sensitivity of certain cancers to standard chemotherapeutic agents (Bailey & Hollingsworth, 2013). Here, PPARG is linked to cancer.